Clinical Trial

A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-21.
Status change: Not Yet Recruiting → Recruiting 2026-04-14
Trial Details
NCT Number NCT06995573
Lead Sponsor NSC-Therapeutics
Collaborators: NeuroScios GmbH
Conditions Alzheimer Disease
Enrollment 90 participants
Start Date 2025-08-25
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-17